eumovate eczema and dermatitis 0.05% cream
haleon uk ltd - clobetasone butyrate - cutaneous cream - 500microgram/1gram
clobaderm 0.05 %w/w cream
auden mckenzie (pharma division) ltd - clobetasol propionate - cream - 0.05 %w/w - corticosteroids, very potent (group iv)
dermal 0.05% cream
tabuk pharmaceutical manufacturing co. - clobetasol propionate - cream - 0.05 %
betamesol 0.05% cream
proge farm s.r.l. baluardo la marmora, 4 - 28100 - novara, italy - betamethasone dipropionate - cream - betamethasone dipropionate 0.05 % (w/w) - corticosteroids, dermatological preparations
androderm- testosterone patch
allergan, inc. - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - testosterone 2 mg in 1 d - androderm is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. these men usually have low serum testosterone concentrations and gonadotropins (fsh, lh) above the normal range. - hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. these men have low testosterone serum concentrations but have gonadotropins in the normal or low range. limitations of use - safety and efficacy of androderm in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. - safety and efficacy of andro
clobaderm 0.05% cream
auden mckenzie (pharma division) ltd - clobetasol propionate - cutaneous cream - 500microgram/1gram
clobaderm 0.05% cream
accord-uk ltd - clobetasol propionate - cutaneous cream - 500microgram/1gram
fentanyl transdermal system- fentanyl transdermal system patch, extended release
lake erie medical dba quality care products llc - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 50 ug in 1 h - fentanyl transdermal system is a transdermal formulation of fentanyl indicated for the management of persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is required for an extended period of time, and the patient cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for a week or longer. fentanyl transdermal system is contraindicated in the following patients and situations due to the risk of fatal respiratory depression: - in patients who are not opioid‑tolerant [see warnings and precautions (5.2)]. - in the management of acute or intermittent pain, or in patients who require opioid analgesia for a short period of tim
dermol
viatris limited - clobetasol propionate 0.05%{relative}; ; clobetasol propionate 0.05%{relative} - topical ointment - 0.05% w/w - active: clobetasol propionate 0.05%{relative} excipient: propylene glycol sorbitan sesquioleate white soft paraffin active: clobetasol propionate 0.05%{relative} excipient: propylene glycol sorbitan sesquioleate white soft paraffin - treatment of resistant dermatoses such as psoriasis (excluding widespread plaque psoriasis), recalcitrant eczemas, lichen planus and discoid lupus erythematosus and other skin conditions which do not respond satisfactorily to less active steroids.
celestoderm v/2 cream
bausch health, canada inc. - betamethasone (betamethasone valerate) - cream - 0.05% - betamethasone (betamethasone valerate) 0.05% - anti-inflammatory agents